Abstract
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects*
-
Antibodies, Monoclonal, Humanized / adverse effects*
-
Cardiovascular Diseases / chemically induced
-
Eye Diseases / chemically induced
-
Gastrointestinal Diseases / chemically induced
-
Hemorrhage / chemically induced
-
Humans
-
Intravitreal Injections / adverse effects*
-
Kidney Diseases / chemically induced
-
Retinal Diseases / drug therapy*
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors*
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Vascular Endothelial Growth Factor A